Publications by authors named "D A Furst"
Objective: This study aimed to expand the understanding of the patient with psoriatic arthritis (PsA) experience and to compare/contrast patient and clinician prioritization of PsA dimensions.
Methods: We conducted four patients with PsA focus groups across three US rheumatology practices using mixed methods to identify attributes of PsA important to patients. Combination with extant attributes of PsA identified by a steering committee created a comprehensive list of attributes.
Article Synopsis
- - A study compared the outcomes of autologous hematopoietic stem cell transplantation (AHSCT) using unmodified peripheral blood stem cells (PBSC) with maintenance therapy (mycophenolate mofetil) versus a previously studied method that involved CD34+ selected PBSC in patients with diffuse systemic sclerosis (SSc).
- - In this trial involving 20 high-risk SSc patients, the 5-year overall survival (OS) was estimated at 85%, and event-free survival (EFS) was 75%, indicating promising results with this new approach.
- - The research highlighted a potential risk factor for poor outcomes in patients undergoing AHSCT: having a low estimated glomerular filtration rate (
Oral health in systemic sclerosis: A scoping review.
J Scleroderma Relat Disord
May 2024
Article Synopsis
- Limited research on oral health in systemic sclerosis prompts a scoping review to identify studies related to quality of life across five key domains: symptoms, functional impacts, psychosocial factors, patient-related variables, and self-care practices.
- From 1460 studies reviewed, only 91 were included, with most being conducted in Europe or North America and featuring small participant numbers, indicating a significant gap in comprehensive research.
- The majority of studies focus on oral manifestations and symptoms, with fewer addressing other crucial areas; further systematic reviews and larger studies are essential to improve understanding and care for systemic sclerosis patients.
Objective: To examine the association between study characteristics and the harms reported in randomised controlled trials (RCTs) on biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with inflammatory arthritis (IA).
Methods: We searched MEDLINE for all Cochrane reviews and for systematic reviews published since April 2015. RCTs were eligible if they included patients with IA receiving b/tsDMARD, compared with any comparator arm.
Establishing a strategy for sequencing of T cell-redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunologic impact of bispecific T cell-engaging antibodies (BsAb) as bridging therapy (BT) to subsequent B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapies in 52 patients with RRMM. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared with chemotherapy, anti-CD38, or anti-SLAMF7 antibody-based regimens (46%).
View Article and Find Full Text PDF